



ASX RELEASE

29 January 2024

OPERATIONAL UPDATE

Melbourne, Australia; 29 January 2024: Jayex Technology Limited (ASX: JTL) (**Jayex** or **Company**), a leading UK provider of integrated e-health SaaS products for General Practice, today is pleased to provide an update on a recent notable event for the Company.

JOINT VENTURE WITH MORPh CLINICAL SERVICES LIMITED

As part of expanding the scope of services beyond patient engagement, the Company has entered into a joint venture with **MORPh** Clinical Services Limited to provide a new clinically focused package of services to UK based General Practice clinics.

The joint venture, Symbia Health Limited (**Symbia**), will leverage the combined capabilities of the Company and **MORPh** Clinical Services to provide services to:

- UK NHS customers (GP clinics) managing disease prevalence ensuring patients get access to the appropriate treatments for their conditions.
- Enable UK pharmaceutical and medical device industry customers to achieve their market access strategies.

Symbia is 50/50 joint venture between the Company and **MORPh** Clinical Services.

MORPh Clinical Services is a leading provider of clinical services to the NHS and pharmaceutical industry, focussing on improving patient access to treatment and review thereby improving patient outcomes, as well as supporting cost-effective prescribing and enhancing the value of medicines to patients and the healthcare economy.

MORPh is a pharmacist-led provider of Clinical Services and Training for Pharmacists and Pharmacy Technicians in the NHS, with over 11,000 current pharmacist members on the **MORPh** training network, currently working with around 80% of the NHS across the group.

Jayex CEO, Rob Hadley, commented “We identified over a year ago that the expansion into clinical services presented a huge opportunity for Jayex. However, we also knew that we needed the right partner to support that expansion. In Morph Clinical Services we have found the ideal partner. The respective capabilities of our businesses are highly complementary, but of equal importance is the fact that we have very compatible company cultures. I am extremely excited about the opportunity that Symbia Health brings for the future of both of our businesses.”





Rachel Jaynes of Morph Clinical Services said “We have been looking for a suitable technology partner that could help us realise our goal of expanding Clinical Services, with Jayex we have a partner that has the right software development capabilities and a significant number of potential clients. Symbia Health represents a very exciting development for us as a group, bringing together our respective teams to develop and harness software to improve patient care. The synergy and alignment between our organisations is very natural and encouraging as we embark upon this journey with Jayex”.

This announcement is authorised for release to the market by the Board of Jayex Technology Limited.

Contacts for further information:

Investor Enquiries
Chief Executive Officer
Rob Hadley
r.hadley@jayex.com
+44 (0) 778 666 2917

Non-Executive Chairman
Michael Boyd
m.boyd@jayex.com
+44 (0) 731 210 6490

